TuHURA Biosciences (NASDAQ:HURA - Free Report) - Equities researchers at HC Wainwright lifted their Q2 2026 earnings estimates for TuHURA Biosciences in a research report issued on Thursday, April 3rd. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.10) per share for the quarter, up from their prior estimate of ($0.11). HC Wainwright has a "Buy" rating and a $12.00 price objective on the stock.
HURA has been the topic of a number of other research reports. Rodman & Renshaw began coverage on TuHURA Biosciences in a research report on Thursday, December 19th. They set a "buy" rating and a $11.00 price target on the stock. RODMAN&RENSHAW upgraded TuHURA Biosciences to a "strong-buy" rating in a research report on Thursday, December 19th.
Get Our Latest Stock Analysis on HURA
TuHURA Biosciences Stock Up 9.0 %
Shares of NASDAQ:HURA traded up $0.35 during trading on Monday, reaching $4.22. 270,604 shares of the company's stock traded hands, compared to its average volume of 273,057. TuHURA Biosciences has a fifty-two week low of $1.80 and a fifty-two week high of $7.93. The stock has a 50-day simple moving average of $3.29.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of HURA. Geode Capital Management LLC acquired a new position in shares of TuHURA Biosciences during the fourth quarter valued at approximately $1,084,000. Suncoast Equity Management purchased a new stake in shares of TuHURA Biosciences during the fourth quarter worth approximately $421,000. Apollon Wealth Management LLC purchased a new stake in shares of TuHURA Biosciences during the fourth quarter worth approximately $253,000. Northern Trust Corp acquired a new position in TuHURA Biosciences in the 4th quarter valued at $234,000. Finally, Squarepoint Ops LLC purchased a new position in TuHURA Biosciences in the 4th quarter valued at $223,000. 0.62% of the stock is owned by hedge funds and other institutional investors.
About TuHURA Biosciences
(
Get Free Report)
TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
Further Reading
Before you consider TuHURA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TuHURA Biosciences wasn't on the list.
While TuHURA Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
